SCHEMBL21372956

SCHEMBL21372956

COc1cccc(N=C(NO)c2ccnc3nc[nH]c23)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
CYP3A4 P08684 2/20 0.46
CYP3A5 P20815 1/20 0.46
BRD4 O60885 3/20 0.43
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR3A P46098 1/20 0.41
HTR3D Q70Z44 1/20 0.41
HTR3C Q8WXA8 1/20 0.41
TAAR1 Q96RJ0 1/20 0.40
LRRK2 Q5S007 1/20 0.40
CDC7 O00311 1/20 0.40
DBF4 Q9UBU7 1/20 0.40
SIGMAR1 Q99720 1/20 0.39
QPCT Q16769 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18248929 0.84 HTR3E (0.49) SMN1; SMN2NPC1LMNAHTTRAB9A
SCHEMBL21372715 0.84 IDO1 (0.46) IDO1CYP3A4CYP3A5CDC7DBF4
SCHEMBL21372902 0.84 IDO1 (0.46) IDO1LMNACYP3A4CYP3A5HTR3E
SCHEMBL21372871 0.83 IDO1 (0.47) IDO1NPC1RAB9ACYP3A4BRD4
SCHEMBL21372968 0.81 IDO1 (0.41) IDO1SMN1; SMN2CYP3A4BRD4
SCHEMBL21372683 0.80 IDO1 (0.46) IDO1LMNAHTR3EHTR3BHTR3A
SCHEMBL21373029 0.80 IDO1 (0.39) IDO1SMN1; SMN2LMNACYP3A4CYP3A5
SCHEMBL18224640 0.80 CYP3A4 (0.52) SMN1; SMN2NPC1LMNAHTTRAB9A
SCHEMBL18224639 0.80 CYP3A4 (0.52) SMN1; SMN2NPC1LMNAHTTRAB9A
SCHEMBL21373009 0.78 HTT (0.40) IDO1NPC1HTTRAB9ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3294732-B1 BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE GILEAD SCIENCES INC (US) 2019-09-25 EP claimed